IgG Next Generation (BT595)
Проводит Биотест АГ
Страница компанииAn Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT02810444/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 2–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 81 чел. во всех странах исследования.
- Плановая дата окончания (04.2020) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 26
Критерии включения
- Criteria for inclusion:
- Written informed consent/assent obtained from subjects/subjects' parent(s) or legally acceptable representative indicating that they understood the purpose of, and procedures required for the study and are willing to participate in it.
- Male or female, aged 2 through 75 years, inclusive.
- Diagnosis of PID with impaired antibody production, ie:
- \- Diagnosis of common variable immunodeficiency (CVID) as defined by the European Society for Immunodeficiencies (ESID)/Pan American Group for Immunodeficiency (PAGID) diagnostic criteria.
- \- X-linked agammaglobulinaemia (XLA) as defined by ESID/PAGID diagnostic criteria.
- Established replacement therapy with any immunoglobulin for intravenous administration (IVIg) reference preparation during the previous 6 months, including documentation of IgG trough levels.
- Established replacement therapy with a single IVIg reference preparation for ≥3 months prior to treatment start with BT595 at a 3 week (Q3W) or 4 week (Q4W) schedule with a constant IVIg dose that did not change by ±20% of the mean dose, regular dosage intervals, and at least 1 IgG trough level of ≥5 g/L during the previous 3 months.
- Criteria for exclusion:
- Pregnancy or unreliable contraceptive measures or lactation period (females only).
- Known intolerance to immunoglobulins or comparable substances (eg, vaccination reaction).
- Known intolerance to proteins of human origin or known allergic reactions to components of the study product.
- Participation in another clinical study within 30 days before entering the study or during the study and/or previous participation in this study.
- Employee or direct relative of an employee of the contract research organization, the study site, or Biotest.
- Acquired medical conditions known to cause secondary immune deficiency, such as chronic lymphatic leukemia, lymphoma, multiple myeloma, as well as protein losing enteropathies and hypoalbuminemia.
- Other medical condition, laboratory finding, or physical examination finding that precludes participation.
- Recent febrile illness that precludes or delays participation.
- Active infection and receiving antibiotic therapy for the treatment of this infection at the time of screening. Note: if the subject was deemed to be a screen failure due to a nonserious active infection requiring antibiotic therapy, the subject may have been rescreened after the initial screening.
- Therapy with systemic steroids or other immunosuppressant drugs at the time of enrollment (current daily use of corticosteroids, ie, >10 mg prednisone equivalent/day for >30 days. Intermittent corticosteroid use during the study was allowable, if medically necessary).
- History of thrombotic events (including myocardial infarction, cerebral vascular accident \[including stroke\], pulmonary embolism, and deep vein thrombosis) within the 6 months before treatment start with BT595 or the presence of significant risk factors for thrombotic events.
- Therapy with live-attenuated virus vaccines within 3 months before start of the study.
- Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA.
- Positive diagnosis of hepatitis B or hepatitis C.
- Positive human immunodeficiency virus (HIV) test.
- History of drug or alcohol abuse within the 12 months before treatment start with BT595.
- Inability or lacking motivation to participate in the study.
Источник: ClinicalTrials.gov, NCT02810444 · запись обновлена в реестре 20 июля 2023.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 8
- Rate of Acute Serious Bacterial Infections — approx. 12 month treatment period
Цель исследования
This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)
Где проходит
0 центровЦентры в реестре не указаны.
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02810444 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.